Erlotinib Completed Phase 2 Trials for Recurrent Cervical Cancer / Cervical Squamous Cell Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00031993Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix